TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF. Invented by TransCode Co-Founder and CTO, Dr. Zdravka Medarova, and her colleagues at Massachusetts General Hospital, the technology represents another potential advancement in the diagnosis and treatment of cancer.
Clarity Pharmaceuticals announced that the first patient in its phase1/2theranostic trial, which is testing 64Cu/67Cu SAR-bisPSMA theranostic product in people with metastatic castrate-restant prostate cancer, has been given a dose. The promising preclinical and clinical result so far support clarity’s investigation of the optimised SAR-bisPSMA product in additional oncology indications where the theranostic approach may be useful.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5501
Published Date: Jan 05, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing incidences of cancer and numerous innovations are the major factors driving the growth of the radiotheranostics market.
The market size of radiotheranostics is anticipated to attain a CAGR of 14% over the forecast period, i.e., 2024-2036.
The major players in the market are Clarity Pharmaceuticals, Ariceum Therapeutics GmbH, Novartis AG, Bayer AG, Progenics Pharmaceuticals, Inc., Telix Pharmacuticals Limited, ITM Radiopharma, and others.
The targeted therapeutic segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.